Key facts
- Company type
- Public
- Traded as
- Nasdaq : GILD Nasdaq-100 component S&P 100 component S&P 500 component
- Industry
- Pharmaceutics Biotechnology
- Founded
- June 22, 1987 ; 38 years ago ( 1987-06-22 )
- Founder
- Michael L. Riordan
- Headquarters
- Foster City, California , United States
- Area served
- Worldwide
- Key people
- Daniel O'Day ( chairman and CEO ) Andrew Dickinson ( CFO ) Tomáš Cihlář ( vice president , and senior director, Biology)
- Products
- AmBisome Atripla Biktarvy Complera Cayston Descovy Emtriva Epclusa Genvoya Harvoni Hepcludex Hepsera Letairis Lexiscan Livdelzi Macugen Odefsey Ranexa Sovaldi Stribild Sunlenca Tamiflu Truvada Tybost Veklury Vemlidy Viread Vosevi Yescarta Yeztugo Zydelig
- Revenue
- US$ 29.44 billion (2025)
- Operating income
- US$10.02 billion (2025)
- Net income
- US$8.510 billion (2025)
- Total assets
- US$59.02 billion (2025)
- Total equity
- US$22.70 billion (2025)
- Number of employees
- 17,000 (2025)
- Website
- gilead .com
via Wikipedia infobox
Company
GILD- Industry
- Biological Products, (No Diagnostic Substances)
- Exchange
- Nasdaq
- State of incorporation
- DE
- Entity type
- operating
via SEC EDGAR
Research organization · ROR
- Type
- Company, Funder
- Founded
- 1987
- Location
- Foster City, United States
- Status
- Active
GRID grid.418227.a · ISNI 0000 0004 0402 1634
Official website
Gilead Sciences
Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer & inflammation.
gilead.com →Link to the official site · 4,843 chars · not written by Vinony
~30 min read
Encyclopedic overview
Gilead Sciences, Inc. (/ˈɡɪliəd/) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
Excerpted from Wikipedia’s “Gilead Sciences” article, available under the CC BY-SA 4.0 licence.